Puma Bio stock: buy or sell?

PBYI stock price: $6.50 -2.69% At close on October 18th, 2019

Updated on:
October 18th, 2019

1

Shares of Puma Bio closed on October/18 at $6.50 and eased a shocking -2.69%. October 18th was the third red session in a row, sliding in full a -4.28%. On Monday PBYI plummed a bloodcurdling -5.16%.

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to improve cancer care.

Should I buy Puma Bio stock?

Trading stocks requires experience and discipline, and your buying and selling decisions must come following a methodology. Following a trading plan helps to make decisions easier, quicker and with less hesitations. At Stocks2.com, we like to use very simple but trusted and powerful trend following trading strategies. Simple things usually work the best.

Currently, Puma Bio stock doesn't match any of these trading strategies, so our recommendation is not to buy.

Buy setupElegible
New all-time highNo
New 52 week highNo
Price crossing up 200d MANo
100d MA crossing up 200d MANo
This is not a selling recommendation at all, just it's not the best moment to buy if you follow any of these trading strategies.

Is Puma Bio stock a buy?

Banks and financial institutions post stock ratings everyday. At Stocks2.com, we collected 12 ratings published for PBYI stock in the last month.

The general sentiment of these ratings is bearish for PBYI stock, with 4 negative ratings.
Is PBYI a good stock to buy?
DateAnalyst / BrokerPrevious ratingCurrent rating
2019-8-9Cowenn/aHold
2019-8-9Barclaysn/aUnderweight
2019-8-9Barclaysn/aUnderweight
2019-8-12JPMorgan Chase & Co.n/aSell
2019-7-5Cowenn/aHold
2019-5-29Goldman Sachs Groupn/aNeutral
2019-5-10JPMorgan Chase & Co.n/aUnderweight
2019-5-10CitigroupBuyNeutral
2019-3-1Cowenn/aHold
2019-3-1CitigroupBuyBuy
2019-1-3GuggenheimBuyNeutral
2019-1-17Leerink Swannn/aMarket Perform

Puma Bio stock analysis

Daily outlook

Shares of Puma Biotechnology eased a shocking -2.69% and closed at $6.50.

Puma Biotechnology eased a shocking -2.69% and closed at $6.50. For the last 19 days when PBYI stock price broke down the SMA50d line, it slid $-4.27 per share (-39.65%).

PBYI stock chart (daily)

Weekly outlook

Puma Biotechnology shares plummed -8.84% this week, ending at $6.50. This was the third red week in a row, sliding in full a -43.07%.

Once Puma Bio failed to resist above the support, it inescapably dropped deeper. Since price and 40-weeks moving average lines crossed down early April, PBYI fell $-28.96 per share (-81.67%). Trading stocks that are under the 40-weeks (that is, 200-days) moving average mark is not recommended by many experts, as it indicates that the stock has not enough institutional support.

PBYI stock chart (weekly)

Puma Bio stock price history

Puma Bio stock went public on April 24th, 2012 with a price of $13.001. Since then, PBYI stock sliced a -50.00%, with a yearly average of -7.10%.

1: Adjusted price after possible price splits or reverse-splits.

Puma Bio stock historical price chart

PBYI stock reached 52-week highs at $45.90, and all-time highs 2014-08-26 with a price of 279.37.

Puma Bio stock price target is $29.40

Predicting the price evolution of a stock or any financial instrument in a reliable and repeatable way is probably impossible. However, financial institutions invest time and resources to provide the most accurated estimations to help investors to make their decisions. You should not follow the analysts' PBYI stock price predictions in the hope that they will be met as they may be wrong and not met. We found 9 price predictions for Puma Biotechnology stock released in the last 30 days:
PBYI stock price predictions
DateAnalyst / BrokerActionPrevious targetCurrent targetDiff
2019-8-9CowenReiteratesn/a$25.00-
2019-8-9BarclaysReiterates$21.00$9.00-57.1%
2019-8-9BarclaysLowers Target$21.00$9.00-57.1%
2019-8-12JPMorgan Chase & Co.Reiteratesn/a$13.00-
2019-7-5CowenReiteratesn/a$28.00-
2019-5-29Goldman Sachs GroupLowers Target$29.00$24.00-17.2%
2019-5-10JPMorgan Chase & Co.Lowers Target$27.00$19.00-29.6%
2019-3-1CowenReiteratesn/a$68.00-
2019-3-1CitigroupRaises Target$67.00$70.004.5%
(in average)$33.00$29.40-11.0%
Moving in a range from $70.00 and $9.00, the price prediction for Puma Bio stock is $29.40. In average, analysts' outlook on PBYI price forecast is negative, downsizing the forecast by a -11.00% from previous estimations.

Financials and fundamental analysis

Earnings date and Earnings per Share

On February, Puma Bio failed to meet the expectations of the experts and reported a tragic EPS of $-0.80 per share when experts were expecting $-0.92.
PBYI earnings date and EPS evolution
QuarterReporting dateEstimated EPSActual EPSSurprise
2017-Q1-n/a-1.97n/a
2017-Q2-n/a-2.1n/a
2017-Q32017-11-09-2.58-2.07n/a
2017-Q42018-03-01-1.98-1.71n/a
2018-Q12018-05-09-0.75-0.65n/a
2018-Q22018-08-09-1.26-1.17n/a
2018-Q32018-11-01-1.07-0.37n/a
2018-Q42019-02-28-0.92-0.8n/a
2019-Q1-n/an/an/a
2019-Q2-n/an/an/a

Annual financial results

Compared to 2017, last anual turnover report draw a super good increase of 806.60% to $250.99 M dollars. Similarly, its profit margin (compared to sales) skyrocketed to -45.25%, that is $-113.58 million.

PBYI annual Sales and Income evolution
YearSalesYoYIncome/(margin)YoY
2017$28 M-$-291.96 M-1054.6%-
2018$251 M806.60%$-113.58 M-45.3%-61.10%

Quarterly financial results

Puma Bio posted $71.08 M in sales for 2018-Q4, a 13.49% improvement compared to previous quarter. Reported quarter earnings marked $-30.70 million with a profit margin of -43.18%. Profit margin plunged a -20.51% compared to previous quarter when profit margin was -22.67%. When comparing sales to same quarter last year, Puma Biotechnology sales marked an astounding gain and rocketed a 228.95%. Looking back to recent quarterly results, Puma Bio posted 2 positive quarters in a row.
PBYI quarterly Sales and Income evolution
QuarterSales1QoQ2Income1/(margin)QoQ2
2017-Q3$6 M-$-77.18 M-1269.4%-
2017-Q4$22 M255.39%$-64.08 M-296.5%-16.98%
2018-Q1$67 M207.83%$-24.35 M-36.6%-62.01%
2018-Q2$51 M-23.68%$-44.34 M-87.3%82.11%
2018-Q3$63 M23.37%$-14.20 M-22.7%-67.97%
2018-Q4$71 M13.49%$-30.70 M-43.2%116.15%

Puma Bio ownership

When you are planning to invest in a stock, it's worth to have a look its ownership structure.

Management staff in all public traded companies that hold equity is required to report every transaction to the SEC. For Puma Bio, 13.44% of all outstanding shares are owned by its staff.

Bearish positions for PBYI stock account 0.00%, no big difference from last month.

For a better context understanding, the next table shows ownership data compared to other related stocks:

PBYIDAREGSKPFE
Market cap$252.9 M$13.5 M$105.9 B$201.6 B
Total shares38.9 M16.7 M2,490.0 M5,530.0 M
Float shares30.9 M13.9 M2,450.0 M5,520.0 M
  - Institutional holdings (%)100.9%8.1%11.0%76.2%
  - Insider holdings (%)13.4%16.9%0.0%0.0%
Shares in short selling0.0%0.0%0.0%0.0%

Puma Bio summary

Friday, October 18th, 2019
Open$6.64
Close$6.50
Day range$6.48 - $6.71
Previous close$6.68
Session gain-2.69%
Average true range$0.63
50d mov avg$10.21
100d mov avg$11.07
200d mov avg$20.38
Daily patternlt01c
Weekly pattern lt06c

Puma Bio performance

Performance as an absolute value is never valid if it's not benchmarked against competitors or related stocks in the industry. In the following table, we compare Puma Bio performance to Dare Bioscience, GlaxoSmithKline and Pfizer:
Stock3m6m12m
PBYIPuma Biotechnolog...-36.27%-80.24%-84.59%
DAREDare Bioscience1.25%-19.80%-14.74%
GSKGlaxoSmithKline5.04%9.28%9.42%
PFEPfizer-13.95%-5.72%-15.19%

Puma Bio competitors

We selected a few stocks to conform a list of Puma Biotechnology competitors to check if you are interested in investing in PBYI: